A cost-utility analysis has shown that CBD in combination with usual care offers a cost-effective treatment option for patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in the Netherlands.
This study, published in the Journal of Health Economics and Outcomes Research, evaluated the economic and clinical benefits of using plant-derived, highly purified CBD (Epidyolex) alongside standard antiseizure medications compared to usual care alone.
LGS and DS are severe, treatment-resistant epileptic disorders that primarily affect infants and young children. In December 2022, Epidyolex was approved for reimbursement in the Netherlands as an adjunctive treatment for seizures associated with these conditions.
Continue reading